Navigation Links
GSK Joins Global Vaccine Alliance to Help Prevent Millions of Children from Contracting Pneumococcal Disease in the World's Poorest Countries

LONDON, March 23 /PRNewswire-FirstCall/ -- GSK (NYSE: GSK) has become one of the first manufacturers to sign a unique agreement with the GAVI Alliance (GAVI) that has the potential to save millions of children from dying in the world's poorest countries. GSK will supply up to 300 million doses of its vaccine Synflorix, for invasive pneumococcal disease, to GAVI over a ten year period.  Pneumococcal disease is a leading cause of death in children under the age of five in developing countries.(i)

The agreement is funded by a ground-breaking mechanism called an Advance Market Commitment (AMC) and is the result of years of planning by GAVI, UNICEF, the World Bank and major donors, who recognised the potential of vaccines to prevent diseases in developing countries. The mechanism is backed by the G8 and was officially launched by the AMC partners and donors on 12 June 2009.

Andrew Witty, CEO of GlaxoSmithKline said: "The coalition that has made this possible is providing new means to transform global public health.  The AMC is precisely the sort of innovative model needed to accelerate access to vaccines for people living in the poorest countries.  The typical 15-20 year 'vaccine gap' between access in developed countries versus the world's poorest countries is unacceptable. This AMC means children in Africa will start to receive Synflorix this year."

The agreement for supply of pneumococcal vaccines has been financed by GAVI, five donor countries – the United Kingdom, Canada, Russia, Norway and Italy – and the Bill & Melinda Gates Foundation.(ii) By guaranteeing the availability of initial purchase funds, the AMC enables vaccine makers to invest in development and manufacturing capacity.  In addition, by contracting significant volumes over the long-term, manufacturers can significantly reduce the cost of their vaccines. Pneumococcal vaccines will be supplied at an approximate reduction of 90% of the cost in developed markets.(iii) Over the ten year period of the agreement, GSK will supply up to 300 million doses of its pneumococcal vaccine, valued at approximately US$1.3 billion.

Jean Stephenne, Chairman and President of GSK Biologicals said: "Today's announcement is a vital step forward for public health in developing countries. A pneumococcal vaccine can mean the difference between life and death, as pneumococcal disease kills nearly one million children each year(iv) and sickens millions more with severe respiratory illnesses(v). We are making good progress to rapidly increase our capacity to supply these new contracted volumes of our vaccine, with the first doses expected to be available in Africa in 2010."

Orin Levine, Executive Director of the International Vaccine Access Center said: "I applaud the groundbreaking partnership of vaccine manufacturers, developing country governments, donors, the World Bank, and the GAVI Alliance that has made the most advanced pneumococcal vaccines available to the world's neediest children at steeply discounted prices and faster than ever before. This year, the Advance Market Commitment will begin saving lives and improving the health of African children and families."

Notes to editors

  • Synflorix helps protect against diseases due to Pneumococcus.  It contains 10 serotypes, three of which – 1, 5, and 14 – were required to be included in the vaccine for the AMC due to the high burden of invasive diseases caused by these serotypes in the developing world.
  • Over the next decade, GSK has committed to provide an average of up to 30 million doses annually, starting with more than a million doses in 2010. GSK will continue to rapidly ramp up supply thereafter to meet contracted volumes.  The company expects to deliver the first doses of its pneumococcal vaccine to Africa later this year.
  • GSK has invested more than US$400 million in a dedicated manufacturing plant in Singapore that will produce several hundred million doses of the vaccine annually in the coming years.
  • Synflorix was the first pneumococcal vaccine to receive WHO 'prequalification' for global use, a regulatory endorsement that is a precondition for participation in the AMC.(vi)

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information, please visit .


(i) GAVI Alliance (2009). Pneumococcal AMC: Frequently asked questions. Accessed 16 March 2010 from:

(ii) GAVI Alliance (2009). AMC Fact Sheet: An innovative way to make vaccines available for children. Accessed 16 March 2010 from:

(iii) GAVI Alliance (2009). AMC Fact Sheet: An innovative way to make vaccines available for children. Accessed 16 March 2010 from:

(iv) GAVI Alliance (2007). The Pneumococcal AMC: Ready to save lives. Accessed 16 March 2010 from:

(v) O'Brien, K et al. The Lancet. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Vol 374; 9693, Pages 893 – 902. 12 September 2009. Accessed 16 March 2010 from:

(vi) World Health Organization (2010). United Nations prequalified vaccines: WHO list of vaccines for purchase by UN agencies as of February 2010. Accessed 16 March 2010 from:

SOURCE GlaxoSmithKline

Back to top



SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network
2. The Chicago Office of McDonald Hopkins Continues to Expand: Healthcare Attorney, Charles F. MacKelvie, Joins the Firms National Healthcare and Healthcare Restructuring Practice Groups
3. Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region
4. CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission
5. Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services
6. Industry Advisor Joins OrthoAccel Technologies, Inc.
7. Worlds #1 Health Brand for Kids Joins Forces With Worlds #1 In-School Childrens Theatre
8. Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC.
9. U.S. Department of Justice Alleges Johnson & Johnson Paid Kickbacks to Steer Nursing Home Prescriptions: Joins Chicago Pharmacist's Whistleblower Case
10. Anne Marie Braham Joins The McGarity Group as Associate Attorney
11. Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National ... 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... networking organization exclusively for professional women, boasting 850,000 members and over 200 operating ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... extremely stressful. At the VA Maryland Health Care System, the Caregiver Support ... patients. “Caregivers have a difficult job. Seventy-four percent report that their role ...
(Date:11/30/2015)... ... 30, 2015 , ... Thermi™, a world leader in thermistor-regulated ... ThermiRFR temperature controlled radiofrequency platform has received CE marking and may now be ... temperature as a clinical endpoint. The technology has been available in the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... DUBLIN , Dec. 1, 2015 Research ... of the "Global Mouth Ulcer Treatment Market 2015-2019" ... --> --> According to the report, ... of the global population now affected by them. The ... hormonal imbalances, and tobacco smoking. Mouth disorders are also ...
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... , Nov. 30, 2015  QT Vascular Ltd., together ... together with its subsidiaries, TriReme Medical LLC and Quattro ... engaged in the design, assembly and distribution of advanced ... disease, is pleased to announce that a three-judge panel ... of Appeals for the Federal Circuit ("Federal Circuit") has ...
Breaking Medicine Technology: